May 5, 2016
Recommended Topic Related To:


"The US Food and Drug Administration (FDA) has approved an injectable, long-acting version of Alkermes Inc's atypical antipsychotic aripiprazole to treat adults with schizophrenia.

Aripiprazole lauroxil (Aristada) is administere"...



How Supplied


Treatment-Resistant Schizophrenia

VERSACLOZ is indicated for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment. Because of the significant risk of agranulocytosis and seizure associated with its use, VERSACLOZ should be used only in patients who have failed to respond adequately to standard antipsychotic treatment [see WARNINGS AND PRECAUTIONS].

The effectiveness of clozapine in treatment-resistant schizophrenia was demonstrated in a 6- week, randomized, double-blind, active-controlled study comparing clozapine and chlorpromazine in patients who had failed other antipsychotics [see Clinical Studies].

Reduction In The Risk Of Recurrent Suicidal Behavior In Schizophrenia Or Schizoaffective Disorder

VERSACLOZ is indicated for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for reexperiencing suicidal behavior, based on history and recent clinical state. Suicidal behavior refers to actions by a patient that put him/herself at risk for death.

The effectiveness of clozapine in reducing the risk of recurrent suicidal behavior was demonstrated over a two-year treatment period in the InterSePT™ trial [see Clinical Studies].


Required Laboratory Testing Prior To Initiation And During Therapy

Prior to initiating treatment with VERSACLOZ, obtain a complete blood count (CBC) with differential. The absolute neutrophil count (ANC) must be greater than or equal to 2000/mm³ and the WBC must be greater than or equal to 3500/mm³ in order to initiate treatment. To continue treatment, the ANC and WBC must be monitored regularly [see WARNINGS AND PRECAUTIONS].

Dosing Information

The starting dose is 12.5 mg once daily or twice daily. The total daily dose can be increased in increments of 25 mg to 50 mg per day, if well-tolerated, to achieve a target dose of 300 mg to 450 mg per day (administered in divided doses) by the end of 2 weeks. Subsequently, the dose can be increased once weekly or twice weekly, in increments of up to 100 mg. The maximum dose is 900 mg per day. To minimize the risk of orthostatic hypotension, bradycardia, and syncope, it is necessary to use this low starting dose, gradual titration schedule, and divided dosages [see WARNINGS AND PRECAUTIONS].

Important Administration Instructions

VERSACLOZ Oral Suspension is administered to the mouth by the oral syringes provided (1 mL or 9 mL). After shaking the bottle for 10 seconds prior to each use, the syringe adaptor is pressed on top of the bottle. The oral syringe (1 mL or 9 mL) is filled with air, and inserted into the adaptor. The air is dispelled into the bottle and then the bottle is turned upside down. The prescribed amount of the suspension is drawn from the bottle and dispensed directly to the mouth. The prescribed dose should be administered immediately after it is prepared. Do not draw a dose and store it in the syringe for later use. After use, the oral syringe may be washed with warm water and dried for next use. The bottle may be closed with the same cap without removing the bottle adaptor. Educate patients and caregivers on the steps to administer

VERSACLOZ as described in the Patient Instructions for Use.

VERSACLOZ can be taken with or without food [see Pharmacokinetics].

Maintenance Treatment

Generally, it is recommended that patients responding to VERSACLOZ continue maintenance treatment on their effective dose beyond the acute episode.

Discontinuation Of Treatment

In the event of planned termination of VERSACLOZ therapy, reduce the dose gradually over a period of 1 to 2 weeks. If abrupt discontinuation is necessary (because of agranulocytosis or another medical condition, for example), monitor carefully for the recurrence of psychotic symptoms and symptoms related to cholinergic rebound such as profuse sweating, headache, nausea, vomiting, and diarrhea.

Re-Initiation Of Treatment

When restarting VERSACLOZ in patients who have discontinued VERSACLOZ (i.e., 2 days or more since the last dose), re-initiate with 12.5 mg once daily or twice daily. This is necessary to minimize the risk of hypotension, bradycardia, and syncope [see WARNINGS AND PRECAUTIONS]. If that dose is well tolerated, the dose may be increased to the previously therapeutic dose more quickly than recommended for initial treatment.

Dosage Adjustments With Concomitant Use Of CYP1A2, CYP2D6, CYP3A4 Inhibitors Or CYP1A2, CYP3A4 Inducers

Dose adjustments may be necessary in patients with concomitant use of: strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, or enoxacin); moderate or weak CYP1A2 inhibitors (e.g., oral contraceptives, or caffeine); CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline); CYP3A4 inducers (e.g., phenytoin, carbamazepine, St. John's wort, and rifampin); or CYP1A2 inducers (e.g., tobacco smoking) (Table 1) [see DRUG INTERACTIONS].

Table 1: Dose Adjustment in Patients Taking Concomitant Medications

Co-medications Scenarios
Initiating VERSACLOZ while taking a co-medication Adding a co-medication while taking VERSACLOZ Discontinuing a co-medication while continuing VERSACLOZ
Strong CYP1A2 Inhibitors Use one third of the VERSACLOZ dose. Increase VERSACLOZ dose based on clinical response.
Moderate or Weak CYP1A2 Inhibitors Monitor for adverse reactions. Consider reducing the VERSACLOZ dose if necessary. Monitor for lack of effectiveness. Consider increasing VERSACLOZ dose if necessary.
CYP2D6 or CYP3A4 Inhibitors
Strong CYP3A4 Inducers Concomitant use is not recommended. However, if the inducer is necessary, it may be necessary to increase the VERSACLOZ dose. Monitor for decreased effectiveness. Reduce VERSACLOZ dose based on clinical response.
Moderate or weak CYP1A2 or CYP3A4 Inducers Monitor for decreased effectiveness. Consider increasing the VERSACLOZ dose if necessary. Monitor for adverse reactions. Consider reducing the VERSACLOZ dose if necessary.

Renal Or Hepatic Impairment, Or CYP2D6 Poor Metabolizers

It may be necessary to reduce the VERSACLOZ dose in patients with significant renal or hepatic impairment, or in CYP2D6 poor metabolizers [see Use In Specific Populations].


Dosage Forms And Strengths

VERSACLOZ is available as a free-flowing yellow oral suspension. Each mL contains 50 mg of clozapine.

Oral Suspension

Free-flowing, yellow suspension (50 mg/mL) in amber bottle containing 100 mL. Each box contains 1 x 1 mL oral syringe, 1 x 9 mL oral syringe and 1 bottle adaptor.

NDC No. 18860-121-01

Storage And Handling

Store VERSACLOZ at or below 25°C (77°F). Do not refrigerate or freeze. Protect from light. Shake well for 10 seconds before use.

The suspension is stable for 100 days after initial bottle opening.

Keep out of reach of children.

Distributed by: Jazz Pharmaceuticals Inc., Palo Alto, CA 94304. Revised: July 2013

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 1/23/2014

How Supplied

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Emotional Wellness

Get tips on therapy and treatment.